-
Global Osteoporosis Drugs Market Size, Share And Growth Analysis For 2024-2033
05 Nov 2024 10:00 GMT
… empowerment, as well as global health policies and insurance coverage.
… Union Chimique Belge, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd … Definition Of The Osteoporosis Drugs Market?
Osteoporosis drugs are medications that improve bone …
-
Daewoong Pharmaceutical's Q3 operating profit up 20% on strong sales of BTX, GERD drug
31 Oct 2024 06:18 GMT
… gastroesophageal reflux disease (GERD) drug Fexuclue.
The company posted third … product by French firm Ipsen, marking it as the … Ecuador, and Chile.
The drug’s international presence is set … Nabota and Fexuclue,” Daewoong Pharmaceutical CEO Lee Chang-jae said …
-
Opioids May Harm Reproductive, Bone, Adrenal Hormone Health
29 Oct 2024 12:38 GMT
… , bone, and adrenal hormone health complications, reported a scientific statement … for Pfizer, Ipsen, HRA Pharma, Recordati Rare Diseases, and Consilient Health; an … investigator for Pfizer, Ipsen, …
-
Ipsen's elafibranor recommended for use in patients with rare liver disease
26 Oct 2024 11:45 GMT
Ipsen announced today that the National Institute for Health and Care Excellence (NICE … , U.K. & Ireland Medical Director at Ipsen.
Research demonstrates the significant … of the disease, beyond liver health alone.”
Professor David Jones, Professor …
-
Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis
24 Oct 2024 12:04 GMT
Ipsen’s Iqirvo (elafibranor) has … by the National Institute for Health and Care Excellence (NICE … Medicines and Healthcare products Regulatory Agency granted marketing authorisation to the drug … Montgomery, UK and Ireland medical director at Ipsen, said: “NICE’s …
-
Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2024 et revoit à la hausse ses prévisions pour l'exercice en cours
23 Oct 2024 05:00 GMT
… progrès dans notre portefeuille de médicaments », a commenté David Loew, directeur … 2024, Eton Pharmaceuticals a conclu un accord avec Ipsen pour acquérir Increlex … proposer nos médicaments aux patients dans plus de 100 pays. Ipsen est …
-
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
23 Oct 2024 05:00 GMT
… the European Medicines Agency. Business development In August 2024, Ipsen entered into … 2024, Eton Pharmaceuticals entered into an agreement with Ipsen to acquire Increlex … a focus on bringing transformative medicines to patients in three therapeutic …
-
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
23 Oct 2024 05:38 GMT
… 2024 European Society for Medical Oncology Congress and … European Medicines Agency.
Business development
In August 2024, Ipsen … Eton Pharmaceuticals entered into an agreement with Ipsen to acquire … focus on bringing transformative medicines to patients in …
-
Ariceum Therapeutics Presents Outstanding Data On Its First-In-Class Radiopharmaceutical Drug 225Ac-Satoreotide At The European Association Of Nuclear Medicine 2024
22 Oct 2024 08:59 GMT
… development
Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE … all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the … is to advance nuclear medicine through personalized healthcare, innovation in diagnosis and …
-
Intercept’s liver disease drug Ocaliva faces FDA approval delay
20 Oct 2024 08:27 GMT
… (PDUFA) date for the drug’s supplemental New Drug Application (sNDA) being … June recommendation from the European Medicines Agency’s (EMA) Committee for … company of Pharmaceutical Technology.
In September 2024, the EC gave Ipsen’s …
About
© 1995-2024